Culmination Bio

Executive Summary

Culmination Bio is a private biotech company headquartered in Salt Lake City, founded in 2022, that leverages a unique longitudinal dataset of de-identified patient records spanning over 40 years. The company's core asset is the Apex Intelligence Platform, which organizes this comprehensive data lake—enriched with clinical, -omics, and claims data—into searchable Discovery Cohorts for partners. By partnering with technology and biopharmaceutical firms, Culmination Bio aims to develop novel clinical insights, diagnostics, and therapeutics to improve patient outcomes. The platform's ability to unlock decades of real-world evidence positions it as a valuable tool for accelerating drug development and precision medicine. As an early-stage company, Culmination Bio has not yet disclosed total funding or valuation, but its differentiated data asset and strategic partnerships could drive significant value. The company operates at the intersection of genetics, genomics, and digital health, with potential applications across multiple therapeutic areas. While still private and pre-revenue, the platform's scalability and the growing demand for real-world data support its long-term promise. Key risks include competition from other data platform companies and the need to demonstrate partner ROI. Overall, Culmination Bio represents a compelling opportunity in the healthcare data analytics space, with the potential to transform how clinical insights are derived from real-world evidence.

Upcoming Catalysts (preview)

• Q3 2026New Biopharma Partnership Announcement70% success
• Q2 2026Series A Funding Round80% success